The Food and Drug Administration said it approved United Therapeutics Corp’s drug to treat neuroblastoma, a rare cancer that typically occurs in children below 5 years.
Unituxin is the first drug approved to treat high-risk neuroblastoma patients who have a greater chance of tumors recurring or progressing after chemotherapy.
{iframe}http://www.reuters.com/article/2015/03/10/us-united-therapeutics-fda-idUSKBN0M61QA20150310{/iframe}